A study testing whether a GLP-1 medicine, semaglutide, can help people with HIV drink less.

Recruiting now. Registry record last updated May 26, 2026.

Who can join: Adults 18 to 89, have HIV, BMI 23+.
What you take: semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 3.8 years; your own time in it is usually shorter.
What you get: Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 2Sponsor Vanderbilt University Medical CenterDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 200

What this study is for

Primary condition: HIV. Also studied in: Alcohol, Smoking Cigarette, Cardiovascular Disease Prevention.

Full scientific study title: GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV.

Who can join

Age18 to 89SexAnyBMI23 or higher

Adults 18 to 89, have HIV, BMI 23+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Ages 18-89
Prior diagnosis of HIV-1
Affiliated with Vanderbilt Comprehensive Care Clinic
On current ART regimen for at least 90 days prior to study entry with no missed doses for at least 7 consecutive days.
Most recent absolute CD4 count ≥ 300 cells/mm3 and drawn within 12 months of study enrollment

Key exclusion criteria

Known allergy to semaglutide
Currently taking GLP-1 RA (in the past 3 months)
History of diabetes defined by diagnosis in Problems List in medical record
History of pancreatitis
History of gastroparesis

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Tennessee1 site

Vanderbilt University Medical Center
Nashville, Tennessee
Rachel Jones, MS615-421-3508rachel.l.jones3@vumc.org

Follow this trial

We email you if NCT07221214 changes status, adds new sites in your state, or if a similar trial opens for the same condition. No spam, opt out any time.

Timeline

Started enrolling: April 17, 2026. Expected completion: January 31, 2030. Last updated on ClinicalTrials.gov: May 26, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 21, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.